Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological efficacy of efavirenz-based treatment in HIV-positive treatment-naive patients
2008-006188-35Phase 4Completed
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 cohorts), sponsored by Fondazione IRCCS San Gerardo dei Tintori. Primary endpoints: CD4 response at 24 weeks, T-cell activation and proliferation and 6 more. Started Nov 2008; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on 2008-006188-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006188-35.